Latest articles
No of your stocks has realtime/relevant news articles that can be accessed.
Take a look into our News feed to read about recent price changes and analysis.
Sentiment statistics ?
Financial Histories
Please use our Financial history templates to chart, read and compare all 10'Q filings in depth.
Overview
DBV.PADay performance
| DBV.PA | |
|---|---|
| Price | 1.53 |
| Change Pct | 3.09 |
| Change Abs | 0.05 |
| Market Cap | 147.4 million |
| Eps | -1.01 |
| Pe Ratio | -1.52 |
| Outstanding Shares | 96.1 million |
| Volume | 193476 |
| Avg Volume | 122959 |
| Industry | Biotechnology |
| Sector Name | Health Care |
| Country Short Name | FR |
| Announcement Earnings | 2024-02-29 10:59:00+00:00 |
Dividends
There is no dividend data to display. Refer our Dividend calendar for other accurate data.
Risk Profiles
Please sign up and become a member to view all risk profiles.
Peers
NANO.PA
ALCLS.PA
IPH.PA
3 Login now
Focus
Use our 'Focus' approach as text-and chart based summaries of the financial standing for a company. They are solely focussing on the company's market, risks and chances.
DBV.PA
Company descriptions
DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its lead product candidate is Viaskin Peanut, an immunotherapy product, which has completed Phase III clinical trial for the treatment of peanut allergies in 4 to 11 years of age children, adolescents, and adults. The milk-induced company is also developing Viaskin Milk that is in Phase I/II clinical trial for the treatment of Immunoglobulin E (IgE) mediated cow's milk protein allergy (CMPA); Viaskin Egg, a pre-clinical stage product for the treatment of hen's egg allergy;